McKesson (NYSE:MCK) has won a U.S. Department of Veterans Affairs drug distribution contract that could be worth nearly $32 billion over eight years, beating out its top rivals Cardinal Health (NYSE:CAH) and AmerisourceBergen (NYSE:ABC). Winning such a potentially huge contract made McKesson popular on Wall Street and sent shares of the San Francisco-based company up […]
Cardinal Health (NYSE:CAH) has hired the former CEO of the West Wireless Health Institute as the new leader of its medical products and services business. Don Casey Jr.’s tenure as CEO of Dublin, Ohio-based Cardinal’s medical segment is scheduled to begin on April 16, according to a statement from the company. Cardinal’s $9 billion medical […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cardinal Health (NYSE:CAH) will set the price for Navidea Biopharmaceuticals‘ (NYSE Amex:NAVB) cancer drug that could be approved as soon as this summer. While Navidea, developed the drug, called Lymphoseek, Cardinal will distribute it and collect half of its sales in the U.S., Navidea has said. “In the final analysis, Cardinal will set the pricing,” […]
Pharmaceuticals distributor Cardinal Health (NYSE:CAH) is seeking to sell three nuclear pharmacies as part of a settlement with the Federal Trade Commission. The settlement with the FTC required Cardinal to sell the pharmacies after federal regulators charged that Cardinal’s 2009 acquisition of three nuclear pharmacies from Biotech was anticompetitive, according to a statement from the […]
Pharmaceuticals distributor and medical products supplier Cardinal Health (NYSE:CAH) plans to make $90 million in acquisitions this year to boost its business in China. Dublin, Ohio-based Cardinal entered the Chinese market with the $470 million acquisition in 2010 of Chinese drug distributor Yong Yu. Now, Cardinal is looking to make further acquisitions in the country […]
Medical products supplier Cardinal Health (NYSE:CAH) has released a new surgical mask that offers a better fit and features “fog-reduction technology.” Cardinal’s Smart-Seal surgical mask features a “cinch-and-hug,” single-tie design that creates a custom seal around the wearer’s nose and mouth, according to a statement from Dublin, Ohio-based Cardinal. The new mask also boasts closed-cell […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Pharmaceuticals distributor Cardinal Health (NYSE:CAH) has launched a web-based tool to help rheumatology practices better manage infusion therapy patients. Cardinal’s new InfusaTrack software is designed to make it easier for community rheumatology practices to offer in-office infusion therapy, which involves administering medication through a needle or catheter for patients whose conditions are too severe to […]
Facing increased scrutiny from Canadian regulators, Cardinal Health (NYSE:CAH) has been forced to push back the expiration date of its $165 million offer to buy medical products supplier Futuremed Healthcare Products. The offer was originally set to expire today, Dec. 20, but has now been extended until Feb. 6, according to a statement from the […]
Health products distributor Cardinal Health (NYSE:CAH) has topped a list of the top healthcare supply chain groups from influential research firm Gartner. Gartner’s Healthcare Supply Chain Top 25 ranking is based primarily on two metrics: quantitative measures such as financial data and the opinions of industry peers and analysts, according to a statement from Gartner. […]
Cardinal Health (NYSE:CAH) is staring down its top two competitors for a U.S. Department of Veterans Affairs (VA) drug distribution contract that could be worth up to $32 billion. In January, Dublin, Ohio-based Cardinal should know whether it or AmerisourceBergen (NYSE:ABC) or McKesson (NYSE:MCK) has won the giant VA contract, Bloomberg News reported. Since 2004, […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
For pharmaceuticals distributor Cardinal Health (NYSE:CAH), China represents a world of opportunity. Now — after the $470 million acquisition last year of Chinese drug distributor Yong Yu and the recent opening of a new logistics center in Shanghai — Cardinal just needs to figure out which of those opportunities to pursue. In addition to growing […]
Cardinal Health (NYSE:CAH) has teamed up with an East Coast insurer to launch a best clinical practices care program for patients suffering from rheumatoid arthritis. Cardinal’s partnership with CareFirst BlueCross BlueShield involves adding rheumatoid arthritis (RA) to its P4 clinical pathways program, an initiative that helps insurers and physicians to work together to develop evidence-based […]
Pharmaceuticals distributor Cardinal Health (NYSE:CAH) reported increased, adjusted first-quarter earnings, but investors showed only modest enthusiasm as the company’s full-year outlook remained the same. Cardinal reported adjusted earnings from continuing operations of $256 million, or 73 cents per diluted share, compared with $231 million or 66 cents per diluted share a year earlier, according to […]
Cardinal Health (NYSE:CAH) has acquired for $165 million a Canadian medical products supplier that focuses on selling to nursing homes. The purchase of Futuremed Healthcare Products strengthens Dublin, Ohio-based Cardinal’s presence in Canada and offers Cardinal new customers for its existing medical products. Futuremed specializes in selling consumable nursing home supplies and furniture, and equipment […]
Cardinal Health (NYSE:CAH) has secured exclusive North American marketing rights for a recently cleared staph-infection blood test from diagnostics company MicroPhage. In exchange, Dublin, Ohio-based Cardinal has provided MicroPhage with an unspecified amount of operational funding for development and commercialization of new products, according to a statement from MicroPhage. Reached by phone, MicroPhage officials declined […]